Inquiry Basket
Loading ......
Filter By Product Search for
PRG2
PRG2 Full Name
proteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
PRG2 Introduction
Researchers and clinicians investigating immune-mediated inflammation, allergic disorders, or placental biology often encounter complex effector molecules whose biological roles extend far beyond simple markers of immune activation. One such molecule is Proteoglycan 2 (PRG2), also known as bone marrow proteoglycan or major basic protein (MBP), a cationic proteoglycan predominantly stored in the granules of Eosinophils. PRG2 is encoded by the PRG2 gene and is recognized as one of the most abundant and biologically active components released during eosinophil degranulation. Structurally, PRG2 contains multiple post-translational modification sites, including O-glycosylation, N-glycosylation, and a characteristic chondroitin sulfate glycosaminoglycan chain attached at Ser-62, which contributes to its stability and biological activity. Because PRG2 possesses strong cationic and cytotoxic properties, it can interact with cell membranes, pathogens, and extracellular matrix components, thereby participating in host defense while also influencing tissue remodeling and inflammatory signaling.
Beyond its well-known role in eosinophil biology, emerging multi-omics and single-cell transcriptomic studies have expanded the understanding of PRG2 expression in non-hematopoietic tissues. Integrative analyses of human placental single-cell RNA sequencing datasets have revealed that PRG2 is highly and specifically expressed in Extravillous trophoblasts (EVTs), a specialized trophoblast population responsible for invading maternal vasculature during placental development. Interestingly, PRG2 expression appears particularly enriched in EVTs that invade venous and lymphatic vessels, suggesting that it may play a role in regulating trophoblast migration, vascular remodeling, or immune interactions at the maternal–fetal interface. Compared with other trophoblast populations such as Syncytiotrophoblasts, differentiated EVTs show markedly elevated PRG2 expression, supporting the hypothesis that PRG2 may serve as a reliable molecular marker of invasive trophoblast subtypes. Additionally, experimental observations suggest that PRG2 can influence developmental signaling pathways, including the regulation of the transcription factor FOXA2, a key regulator of definitive endoderm differentiation, indicating a potential link between PRG2 activity and early embryonic lineage specification.
From a disease perspective, abnormal PRG2 expression or release has been implicated in a wide range of pathological conditions, particularly those involving chronic inflammation, allergic responses, and tissue damage. Because PRG2 is a potent cytotoxic mediator, excessive release from activated eosinophils can damage epithelial cells and contribute to the pathogenesis of disorders such as Asthma, Eosinophilic Esophagitis, and other eosinophil-associated inflammatory diseases. At the same time, proteomic analyses of clinical datasets have revealed elevated PRG2 protein levels in tumor tissues, including Colorectal Cancer, suggesting that it may participate in shaping the tumor microenvironment or modulating immune cell infiltration. These findings highlight PRG2 as a multifunctional immune effector protein whose activity bridges innate immunity, developmental biology, and disease pathology. Consequently, growing interest in PRG2 as both a biomarker and a potential therapeutic target reflects the broader need to understand how eosinophil-derived mediators influence inflammation, cancer progression, and maternal–fetal immune tolerance.
Alternate Names for PRG2
PRG2; proteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein); MBP; BMPG; MBP1; bone marrow proteoglycan; bone-marrow proteoglycan; proteoglycan 2 preproprotein; natural killer cell activator; eosinophil major basic protein
Loading ......
